Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A).
about
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A)Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle.Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A.Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexiaProspect for pharmacological therapies to treat skeletal muscle dysfunction.Renin-angiotensin system: an old player with novel functions in skeletal muscle.Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMDIGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy.Laminin: loss-of-function studies.Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle CellsLaminin α2 Chain-Deficiency is Associated with microRNA Deregulation in Skeletal Muscle and Plasma.Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy.Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.High, but not low, exercise volume shifts the balance of renin-angiotensin system toward ACE2/Mas receptor axis in skeletal muscle in obese rats.Treating pediatric neuromuscular disorders: The future is now.Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin.
P2860
Q28548194-1D2588B7-CA65-403E-B03A-A70A74A1A968Q30841381-DC830A99-4684-4E15-A5C6-6E43B67BBEC0Q35201194-12ADFEE2-1A04-4704-9E25-80411561D131Q35274694-95DF20E4-00AB-4B0D-9A97-FD070A64EAE5Q37138465-174195B1-C2A4-4FFB-A2EE-D8B190C3CE7EQ38264369-08C6DB6C-B56C-419B-BCC7-E98E91A226B9Q38375202-600E0559-D471-4960-A70E-A9CB71C1826DQ38644294-7832294C-72BD-4127-8BFA-09A2A5D3E828Q38801997-92809FC0-5AF0-4D96-A3C9-BD79A90351B5Q38815433-39D28B4C-6587-4110-88E9-1295C4E7178EQ41854808-E42A0215-D2B5-4866-B482-AFCED67C1341Q42719076-064CACEB-184C-4541-A088-D8B5DDE46110Q42754638-26252160-EABB-451D-B623-FB3DE7B735F8Q47345657-25A31D94-6464-4393-B651-48CEFBE8C4E7Q50544623-6BE6A610-CA6A-46BF-9E49-486A4E2ED90AQ52756417-45F2B35D-A466-4DC9-B4C4-FFD9A9579AAEQ54210538-3CC8B677-8FBC-4D43-AE11-8C22D337B283
P2860
Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Angiotensin II type 1 receptor ...... al muscular dystrophy (MDC1A).
@en
Angiotensin II type 1 receptor ...... congenital muscular dystrophy
@nl
type
label
Angiotensin II type 1 receptor ...... al muscular dystrophy (MDC1A).
@en
Angiotensin II type 1 receptor ...... congenital muscular dystrophy
@nl
prefLabel
Angiotensin II type 1 receptor ...... al muscular dystrophy (MDC1A).
@en
Angiotensin II type 1 receptor ...... congenital muscular dystrophy
@nl
P2093
P2860
P356
P1433
P1476
Angiotensin II type 1 receptor ...... al muscular dystrophy (MDC1A).
@en
P2093
Markus A Ruegg
Sarina Meinen
P2860
P2888
P356
10.1186/2044-5040-2-18
P577
2012-09-03T00:00:00Z
P5875
P6179
1002212491